FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975222023> ?p ?o ?g. }

• W1975222023 endingPage "60" @default.
• W1975222023 startingPage "52" @default.
• W1975222023 abstract "To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC).Thirteen oestrogen receptor-positive, postmenopausal, T2-4, N0-1 BC patients received the LCS combination for 6 months. In these patients we examined the pharmacokinetics of sorafenib and cyclophosphamide, toxicity of the regimen, the clinical response to therapy and changes in the levels of biologically relevant biomarkers.Adequate plasma concentrations of sorafenib were achieved in patients when it was dosed in combination with L+C. The mean plasma concentrations of C were consistently lower following administration of LCS, compared with administration of L+C only. The most common drug-related grade 3/4 adverse events were skin rash (69.3%), hand-foot skin reaction (69.3%) and diarrhoea (46.1%). According to RECIST Criteria, a clinical complete response was observed in 6 of 13 patients. A significant reduction in tumour size, evaluated with MRI, was also observed between baseline and 14 days of treatment in all 13 patients (P=0.005). A significant reduction in SUV uptake, measured by (18)FDG-PET/CT, was observed in all patients between baseline and 30 days of treatment (P=0.015) and between baseline and definitive surgery (P=0.0002). Using modified CT Criteria, a response was demonstrated in 8 out of 10 evaluable patients at 30 days and in 11 out of 13 evaluable patients at the definitive surgery. A significant reduction in Ki67 expression was observed in all patients at day 14 compared with baseline (P<0.00001) and in 9 out of 13 patients at the definitive surgery compared with baseline (P<0.03). There was also a significant suppression of CD31 and VEGF-A expression in response to treatment (P=0.01 and P=0.007, respectively).The LCS combination is feasible and tolerable. The tumour response and target biomarker modulation indicate that the combination is clinically and biologically active." @default.
• W1975222023 created "2016-06-24" @default.
• W1975222023 creator A5003741492 @default.
• W1975222023 creator A5013171716 @default.
• W1975222023 creator A5020078965 @default.
• W1975222023 creator A5022648629 @default.
• W1975222023 creator A5024279311 @default.
• W1975222023 creator A5030552560 @default.
• W1975222023 creator A5033223978 @default.
• W1975222023 creator A5036390189 @default.
• W1975222023 creator A5041293322 @default.
• W1975222023 creator A5050426287 @default.
• W1975222023 creator A5053119054 @default.
• W1975222023 creator A5057041301 @default.
• W1975222023 creator A5060773546 @default.
• W1975222023 creator A5062166707 @default.
• W1975222023 creator A5071319458 @default.
• W1975222023 creator A5071939535 @default.
• W1975222023 creator A5077857211 @default.
• W1975222023 creator A5079450954 @default.
• W1975222023 creator A5079633934 @default.
• W1975222023 creator A5084277964 @default.
• W1975222023 creator A5085943997 @default.
• W1975222023 creator A5088637763 @default.
• W1975222023 creator A5091879703 @default.
• W1975222023 date "2014-12-02" @default.
• W1975222023 modified "2023-10-06" @default.
• W1975222023 title "Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer" @default.
• W1975222023 cites W1520299947 @default.
• W1975222023 cites W1607191879 @default.
• W1975222023 cites W1813571362 @default.
• W1975222023 cites W1973299943 @default.
• W1975222023 cites W1989343097 @default.
• W1975222023 cites W1993785946 @default.
• W1975222023 cites W2003999835 @default.
• W1975222023 cites W2011705265 @default.
• W1975222023 cites W2036377481 @default.
• W1975222023 cites W2036611613 @default.
• W1975222023 cites W2049579456 @default.
• W1975222023 cites W2060370107 @default.
• W1975222023 cites W2061401090 @default.
• W1975222023 cites W2080527870 @default.
• W1975222023 cites W2084847779 @default.
• W1975222023 cites W2086827064 @default.
• W1975222023 cites W2090806526 @default.
• W1975222023 cites W2100086207 @default.
• W1975222023 cites W2100661360 @default.
• W1975222023 cites W2103158778 @default.
• W1975222023 cites W2105529705 @default.
• W1975222023 cites W2112311941 @default.
• W1975222023 cites W2115423963 @default.
• W1975222023 cites W2116177733 @default.
• W1975222023 cites W2116629325 @default.
• W1975222023 cites W2120398882 @default.
• W1975222023 cites W2123534406 @default.
• W1975222023 cites W2123945948 @default.
• W1975222023 cites W2125501362 @default.
• W1975222023 cites W2131528383 @default.
• W1975222023 cites W2139552047 @default.
• W1975222023 cites W2147325805 @default.
• W1975222023 cites W2148532787 @default.
• W1975222023 cites W2151507583 @default.
• W1975222023 cites W2156453405 @default.
• W1975222023 cites W2161425022 @default.
• W1975222023 cites W2163899134 @default.
• W1975222023 cites W2163940216 @default.
• W1975222023 cites W2164484108 @default.
• W1975222023 cites W2263907628 @default.
• W1975222023 cites W4294309380 @default.
• W1975222023 doi "https://doi.org/10.1038/bjc.2014.563" @default.
• W1975222023 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4453610" @default.
• W1975222023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25461806" @default.
• W1975222023 hasPublicationYear "2014" @default.
• W1975222023 type Work @default.
• W1975222023 sameAs 1975222023 @default.
• W1975222023 citedByCount "28" @default.
• W1975222023 countsByYear W19752220232015 @default.
• W1975222023 countsByYear W19752220232016 @default.
• W1975222023 countsByYear W19752220232017 @default.
• W1975222023 countsByYear W19752220232018 @default.
• W1975222023 countsByYear W19752220232019 @default.
• W1975222023 countsByYear W19752220232020 @default.
• W1975222023 countsByYear W19752220232021 @default.
• W1975222023 countsByYear W19752220232022 @default.
• W1975222023 crossrefType "journal-article" @default.
• W1975222023 hasAuthorship W1975222023A5003741492 @default.
• W1975222023 hasAuthorship W1975222023A5013171716 @default.
• W1975222023 hasAuthorship W1975222023A5020078965 @default.
• W1975222023 hasAuthorship W1975222023A5022648629 @default.
• W1975222023 hasAuthorship W1975222023A5024279311 @default.
• W1975222023 hasAuthorship W1975222023A5030552560 @default.
• W1975222023 hasAuthorship W1975222023A5033223978 @default.
• W1975222023 hasAuthorship W1975222023A5036390189 @default.
• W1975222023 hasAuthorship W1975222023A5041293322 @default.
• W1975222023 hasAuthorship W1975222023A5050426287 @default.
• W1975222023 hasAuthorship W1975222023A5053119054 @default.
• W1975222023 hasAuthorship W1975222023A5057041301 @default.
• W1975222023 hasAuthorship W1975222023A5060773546 @default.

• next